Investor Relations

Ensysce Biosciences 2021 Annual Letter

View Letter

Latest Financial Results

Latest Annual Filing

For Fiscal Year Ending Dec 31, 2021

Company Overview

Ensysce Biosciences, Inc. is a clinical stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the fear of and the potential for addiction, opioid misuse, abuse and overdose. Our current development pipeline includes two new drug platforms - an abuse-resistant opioid prodrug technology – the Trypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology - the Multi-Pill Abuse Resistant, or the MPAR™ platform. The TAAP platform is designed to improve the care of patients with chronic pain while reducing the human and economic costs associated with prescription opioid drug abuse. The MPAR™ platform when combined with our TAAP prodrugs is designed not only to prevent abuse of prescription drugs but also to reduce overdose occurrences. Additionally, nafamostat di-mesylate, which is an ingredient in our overdose protection combination products, is also being developed for the intended purpose of treating infection and pulmonary lung diseases.

IR Contacts

Headquarters

Ensysce Biosciences, Inc.
7946 Ivanhoe Ave
Suite 201
La Jolla, CA 92037
T: 858-263-4196
info@ensysce.com

Investor Relations

MZ North America
5055 Avenida Encinas
Suite 130
Carlsbad, CA 92008
T: 203-741-8811

Shannon Devine
shannon@mzgroup.us